Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer

奥西默替尼 肺癌 癌症研究 突变体 医学 癌症 转化(遗传学) 生物 病理 表皮生长因子受体 遗传学 基因 埃罗替尼
作者
Adam J. Schoenfeld,Joseph M. Chan,Daisuke Kubota,Hiroki Sato,Hira Rizvi,Yahya Daneshbod,Jason C. Chang,Paul K. Paik,Michael Offin,Maria E. Arcila,Monika A. Davare,Ujwal Shinde,Dana Pe’er,Natasha Rekhtman,Mark G. Kris,Romel Somwar,Gregory J. Riely,Marc Ladanyi,Helena A. Yu
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:26 (11): 2654-2663 被引量:354
标识
DOI:10.1158/1078-0432.ccr-19-3563
摘要

Abstract Purpose: Patterns of resistance to first-line osimertinib are not well-established and have primarily been evaluated using plasma assays, which cannot detect histologic transformation and have differential sensitivity for copy number changes and chromosomal rearrangements. Experimental Design: To characterize mechanisms of resistance to osimertinib, patients with metastatic EGFR-mutant lung cancers who received osimertinib at Memorial Sloan Kettering Cancer Center and had next-generation sequencing performed on tumor tissue before osimertinib initiation and after progression were identified. Results: Among 62 patients who met eligibility criteria, histologic transformation, primarily squamous transformation, was identified in 15% of first-line osimertinib cases and 14% of later-line cases. Nineteen percent (5/27) of patients treated with first-line osimertinib had off-target genetic resistance (2 MET amplification, 1 KRAS mutation, 1 RET fusion, and 1 BRAF fusion) whereas 4% (1/27) had an acquired EGFR mutation (EGFR G724S). Patients with squamous transformation exhibited considerable genomic complexity; acquired PIK3CA mutation, chromosome 3q amplification, and FGF amplification were all seen. Patients with transformation had shorter time on osimertinib and shorter survival compared with patients with on-target resistance. Initial EGFR sensitizing mutation, time on osimertinib treatment, and line of therapy also influenced resistance mechanism that emerged. The compound mutation EGFR S768 + V769L and the mutation MET H1094Y were identified and validated as resistance mechanisms with potential treatment options. Conclusions: Histologic transformation and other off-target molecular alterations are frequent early emerging resistance mechanisms to osimertinib and are associated with poor clinical outcomes. See related commentary by Piotrowska and Hata, p. 2441
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
田様的应助被兵临城下采纳,获得10
1秒前
冷静怜珊发布了新的文献求助10
1秒前
平和的狍子完成签到 ,获得积分10
2秒前
2秒前
2秒前
3秒前
yydlt完成签到,获得积分10
7秒前
栗心完成签到,获得积分10
7秒前
aaaa的应助被贺贺采纳,获得30
7秒前
周文凯发布了新的文献求助10
8秒前
8秒前
HORIS的应助被冷静怜珊采纳,获得10
9秒前
老的火龙果的应助被时鹏飞采纳,获得10
13秒前
百变怪完成签到,获得积分10
14秒前
怡然的大门完成签到,获得积分10
15秒前
周文凯完成签到,获得积分10
15秒前
快乐星球完成签到,获得积分10
16秒前
打烊完成签到 ,获得积分10
16秒前
supreme辉完成签到,获得积分10
17秒前
18秒前
18秒前
20秒前
20秒前
老的火龙果的应助被时鹏飞采纳,获得10
24秒前
Zesong发布了新的文献求助10
25秒前
28秒前
29秒前
aajhajkahna的应助被den采纳,获得10
29秒前
34秒前
35秒前
打工仔发布了新的文献求助10
35秒前
王卓远发布了新的文献求助10
36秒前
汉堡包的应助被zeus采纳,获得10
36秒前
37秒前
典雅的人生完成签到,获得积分0
37秒前
方啊啊关注了科研通微信公众号
38秒前
小马甲的应助被天真醉薇采纳,获得10
38秒前
CodeCraft的应助被文静萤采纳,获得10
40秒前
wenwei发布了新的文献求助10
41秒前
hbq完成签到,获得积分10
43秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
自動車の空力技術 800
Essentials of Carbohydrate Chemistry and Biochemistry, 4th Edition 800
Organizational Behavior 510
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
Issues in Task-Based Language Teaching 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 化学工程 工程类 有机化学 物理 复合材料 生物化学 内科学 细胞生物学 基因 遗传学 免疫学 冶金 光电子学 癌症研究
热门帖子
关注 科研通微信公众号,转发送积分 7783710
求助须知:如何正确求助?哪些是违规求助? 9322987
关于积分的说明 20392570
捐赠科研通 7372332
什么是DOI,文献DOI怎么找? 3320737
关于科研通互助平台的介绍 2468747
邀请新用户注册赠送积分活动 2336971